Search
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Alprenolol
go.drugbank.com/drugs/DB00866ApprovedWithdrawnAlprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. … One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … [A229668] On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585]
Thiopental
go.drugbank.com/drugs/DB00599ApprovedInvestigationalVet approvedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p920) … It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties.
Products: Pentothal Inj 500mg/syrN,N'-diphenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14192ApprovedCategories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-diphenyl-1,4-phenylenediamineBentonite
go.drugbank.com/drugs/DB11306ApprovedWithdrawnCategories: Compounds used in a research, industrial, or household settingLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnNew Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Cefditoren
go.drugbank.com/drugs/DB01066ApprovedCefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Odronextamab
go.drugbank.com/drugs/DB16684ApprovedInvestigationalThe partial clinical hold was later lifted in May 2021. … [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma